Robert Lim

6.4k total citations · 1 hit paper
56 papers, 4.5k citations indexed

About

Robert Lim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Robert Lim has authored 56 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 26 papers in Pulmonary and Respiratory Medicine and 14 papers in Molecular Biology. Recurrent topics in Robert Lim's work include Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Robert Lim is often cited by papers focused on Colorectal Cancer Treatments and Studies (23 papers), Genetic factors in colorectal cancer (8 papers) and Hepatocellular Carcinoma Treatment and Prognosis (7 papers). Robert Lim collaborates with scholars based in Singapore, Canada and China. Robert Lim's co-authors include Arié Figer, Steven Gallinger, Daniel de Castro, H. Au, Malcolm J. Moore, Wendy R. Parulekar, John Hamm, Keyue Ding, P. Murawa and David Walde and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Robert Lim

54 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

2007 2.9k citations Robert Lim et al. profile →

Peers

Countries citing papers authored by Robert Lim

Since Specialization

Citations

This map shows the geographic impact of Robert Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Lim more than expected).

Fields of papers citing papers by Robert Lim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Lim. The network helps show where Robert Lim may publish in the future.

Co-authorship network of co-authors of Robert Lim

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Lim. A scholar is included among the top collaborators of Robert Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Lim. Robert Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Meta‐Analysis: Utilisation of Hepatocellular Carcinoma Surveillance 2025 ·Alimentary Pharmacology & Therapeutics ·Nicole K. Y. Tang, (unknown), (unknown), Benjamin Koh, (unknown), Robert Lim, Darren Jun Hao Tan, Nicholas Syn, Cheng Han Ng, Mark Muthiah, Pojsakorn Danpanichkul, Karn Wijarnpreecha, Masahito Nakano, Asako Nogami, Atsushi Nakajima, Ming‐Hua Zheng, Kazuhiro Takahashi, (unknown), Mei Chin Lim, Daniel Q. Huang	1
2	Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis 2025 ·Alimentary Pharmacology & Therapeutics ·George Ho, (unknown), Robert Lim, Leonard L.L. Yeo, Benjamin Nah, Boon Chuan Low, Tom Chan, (unknown), (unknown), (unknown), (unknown), Hideki Fujii, Hirokazu Takahashi, Vincent Chen, Mazen Noureddin, Mark Muthiah, Wen Hui Lim, Mohammad Shadab Siddiqui, Eunice X. Tan	1
3	Canadian Society of Thoracic Radiology/Canadian Association of Radiologists Clinical Practice Guidance for Non-Vascular Thoracic MRI 2021 ·Canadian Association of Radiologists Journal ·Elsie T. Nguyen, Hamid Bayanati, Ana-Maria Bilawich, (unknown), Robert Lim, Scott R. Harris, Carole Dennie, Anastasia Oikonomou	3
4	Are growth patterns on MRI in small (< 4 cm) solid renal masses useful for predicting benign histology? 2018 ·European Radiology ·Robert Lim, Matthew D. F. McInnes, (unknown), Trevor A. Flood, Luke T. Lavallée, Nicola Schieda	13
5	Multidisciplinary Retroperitoneal and Pelvic Soft-Tissue Sarcoma Case Conferences: The Added Value that Radiologists Can Provide 2017 ·Current Oncology ·Robert Lim, Ania Z. Kielar, (unknown), (unknown), Carolyn Nessim, Seng Thipphavong	1
6	Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI? 2017 ·European Radiology ·Robert Lim, Trevor A. Flood, Matthew D. F. McInnes, Luke T. Lavallée, Nicola Schieda	54
7	O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study 2016 ·Annals of Oncology ·Ann‐Lii Cheng, Gerardo Cornelio, Lin Shen, Timothy Price, T.-S. Yang, Ik‐Joo Chung, Guanghai Dai, Johnson Lin, Ankur Sharma, Kun‐Huei Yeh, Brigette Ma, Adel Zaatar, Zhenpeng Guan, (unknown), Vichien Srimuninnimit, Thomas Yau, Frank Beier, Sudipto Chatterjee, Robert Lim	1
8	Glucuronidation by UGT1A1 Is the Dominant Pathway of the Metabolic Disposition of Belinostat in Liver Cancer Patients 2013 ·PLoS ONE ·(unknown), Jacqueline Ramı́rez, Winnie Yeo, (unknown), (unknown), Jieying Amelia Lau, (unknown), (unknown), (unknown), Robert Lim, Soo Chin Lee, Paul C. Ho, (unknown), Anthony T.�C. Chan, Sherry S. Ansher, Mark J. Ratain, Boon Cher Goh	56
9	Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: The ELSIE study 2011 ·World Journal of Gastroenterology ·Robert Lim	18
10	A phase II study of fenretinide in patients with hormone refractory prostate cancer: a trial of the Cancer Therapeutics Research Group 2010 ·Cancer Chemotherapy and Pharmacology ·Melissa M. Moore, Martin R. Stockler, Robert Lim, Tony Mok, (unknown), Michael Boyer	31
11	Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre 2010 ·Clinical and Experimental Dermatology ·R. Rajaratnam, C. Mann, P. Balasubramaniam, Jerry Marsden, Saleem Taibjee, (unknown), Robert Lim, Remo Papini, Naiem Moiemen, Huckaby Lewis	66
12	Influence of UGT1A9 intronic I399C4T polymorphism on SN-38 glucuronidation in Asian cancer patients 2008 ·Faculty of Health; Institute of Health and Biomedical Innovation ·Balram Chowbay, Brian C. Goh, Srinivasa Rao Jada, (unknown), Robert Lim, Edwin Sandanaraj, Xiao Shu, Qingyu Zhou, Shufeng Zhou	2
13	Debulking nephrectomy followed by a “watch and wait” approach in metastatic renal cell carcinoma 2008 ·Urologic Oncology Seminars and Original Investigations ·Alvin Wong, (unknown), (unknown), David Consigliere, Kesavan Esuvaranathan, (unknown), Benjamin Chuah, Robert Lim, (unknown)	18
14	Recurring MLH1 deleterious mutations in unrelated Chinese Lynch syndrome families in Singapore 2008 ·Familial Cancer ·(unknown), (unknown), (unknown), Robert Lim, Ross A. Soo, Jiayi Guo, Soo Chin Lee	17
15	Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients 2007 ·The Pharmacogenomics Journal ·Edwin Sandanaraj, (unknown), Xiao Shu, Robert Lim, (unknown), Qingyu Zhou, Sheng Zhou, Boon Cher Goh, Balram Chowbay	28
16	Irofulven as first line therapy in recurrent or metastatic gastric cancer: a phase II multicenter study by the Cancer Therapeutics Research Group (CTRG) 2006 ·Cancer Chemotherapy and Pharmacology ·Winnie Yeo, Michael Boyer, Hyun Cheol Chung, Simon Yew Kuang Ong, Robert Lim, Benny Zee, Brigette Ma, (unknown), Frankie Mo, Enders K. Ng, Rosemary Ho, Stephen Clarke, Jieun Roh, Philip Beale, Sun Young Rha, Hei‐Cheul Jeung, Ross A. Soo, Brian C. Goh, Anthony T.�C. Chan	14
17	Pharmacogenetics of SLCO1B1 gene and the impact of 1b and 15 haplotypes on irinotecan disposition in Asian cancer patients 2006 ·Pharmacogenetics and Genomics ·Xiaoqiang Xiang, Srinivasa Rao Jada, (unknown), Lu Fan, Lai Tham, (unknown), Soo Chin Lee, Robert Lim, (unknown), Boon Cher Goh, Eng Huat Tan, Balram Chowbay	66
18	Clinical and molecular characteristics of hereditary non‐polyposis colorectal cancer families in Southeast Asia 2005 ·Clinical Genetics ·(unknown), (unknown), Robert Lim, Ross A. Soo, Evelyn Siew-Chuan Koay, Manuel Salto‐Tellez, (unknown), (unknown)	32
19	Liver Resection after Irinotecan, 5-Fluorouracil, and Folinic Acid for Patients with Unresectable Colorectal Liver Metastases: A Multicenter Phase II Study by the Cancer Therapeutic Research Group 2005 ·Medical Oncology ·Wing Ming Ho, Brigette Ma, Tony Mok, Winnie Yeo, Paul B.S. Lai, Robert Lim, Jane Koh, (unknown), Ann D. King, C. K. Leow, Anthony T.�C. Chan	42
20	APC I1307K and the E1317Q variants are not present in Chinese colorectal cancer patients 2004 ·Genetics in Medicine ·Jiayi Guo, Robert Lim, Ross A. Soo, Adrian Leong, Soo Chin Lee	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact